AHK-Cu
Copper Tripeptide-3 · L-Alanyl-L-Histidyl-L-Lysine Copper(II) · Ala-His-Lys-Cu · Alanine/Histidine/Lysine Polypeptide Copper
Last updated
At a glance
Overview
AHK-Cu is the copper tripeptide that the hair-retention side of the looksmaxxing community reaches for when the goal is specifically follicle trophism — not skin remodeling, not wound healing, but dermal papilla cell survival and anagen extension. Where GHK-Cu earned its reputation in anti-aging skincare, AHK-Cu was isolated and characterized in a 2007 Seoul National University study as a direct stimulant of human hair follicle elongation ex vivo and of dermal papilla cell proliferation in culture. That's the paper the entire community protocol rests on.
The practical appeal is straightforward: AHK-Cu is non-hormonal, has no HPTA interaction, no sexual side-effect profile, and layers cleanly on top of the fin/min foundation — or alongside topical AR antagonists like RU58841 for users who've discontinued oral 5-ARIs. It's the piece of the hair stack that targets the follicle's survival and vascular support pathways rather than DHT suppression or follicle-cycle modulation, which is why experienced users run it with minoxidil and a 5-AR inhibitor or AR antagonist, not instead of them.
"The tripeptide-copper complex promoted proliferation of human DPCs at 10⁻¹² to 10⁻⁹ M, and elongated human hair follicles ex vivo." — Pyo et al., Archives of Pharmacal Research (2007)
The sections below cover documented AHK-Cu concentrations and vehicle formulation, the biphasic dose-response that matters more here than raw concentration, co-formulation with GHK-Cu, microneedling potentiation, stacking onto a fin/min or RU58841 foundation, and the realistic 3-to-6-month timeline for evaluating response.
How AHK-Cu works
AHK-Cu is a copper-bound tripeptide (Ala-His-Lys-Cu²⁺) engineered as a follicle-trophic analog of the better-known GHK-Cu, but with an N-terminal alanine that resists dermal aminopeptidases and a mechanism profile weighted toward the dermal papilla rather than general skin remodeling. It works at the level of the hair follicle's signaling hub — not at the androgen axis — which is why it layers cleanly on top of a fin/min or topical AR-antagonist foundation rather than replacing any of it.
Dermal Papilla Cell Proliferation#
The dermal papilla cell (DPC) is the signaling control room at the base of each follicle — it decides how long anagen lasts and how thick the shaft produced during that phase will be. AHK-Cu at picomolar to low-nanomolar concentrations directly drives DPC mitogenesis and extends the anagen-phase window.
"The tripeptide-copper complex promoted proliferation of human DPCs at 10⁻¹² to 10⁻⁹ M, and elongated human hair follicles ex vivo." — Pyo HK et al., Archives of Pharmacal Research, 2007
Practically, this is the mechanism that translates into reduced shedding and sustained density when AHK-Cu is layered onto a hair stack for 3–6 months. The dose-response is biphasic — concentrations at or above 10⁻⁸ M actually inhibit follicle elongation in the same model — which is the mechanistic reason community formulators should ignore the "more is better" instinct and stay in the 0.1–0.5% topical range.
Anti-Apoptotic Signaling in the Follicle#
Androgenetic alopecia is, in large part, a story of DPCs being nudged into apoptosis earlier than they should be. AHK-Cu raises the Bcl-2/Bax ratio and sharply reduces cleaved caspase-3 and PARP cleavage fragments in cultured DPCs, tilting the balance back toward follicle survival and delaying catagen entry. The practical read-through: follicles that would otherwise miniaturize during an AAS cycle or an aggressive cut are given a survival signal, buying time for the rest of the stack (5-AR inhibition, AR antagonism, minoxidil-driven perfusion) to do its work.
VEGF Upregulation and Perifollicular Vascularization#
Copper tripeptides as a class upregulate vascular endothelial growth factor and suppress fibrotic TGF-β1 signaling at the dermal level, remodeling the vascular bed around the follicle.
"Copper peptides stimulate the secretion of growth factors such as VEGF and suppress molecules like TGF-β1, modulating perifollicular vascularization and tissue remodeling." — Pickart L & Margolina A, International Journal of Molecular Sciences, 2018
This is the same general axis minoxidil exploits through a different molecular route. Stacking AHK-Cu with topical or oral minoxidil is mechanistically complementary — minoxidil opens and widens existing scalp microvasculature, while copper peptides drive the growth-factor signal that builds new capillary networks around surviving follicles.
Fibroblast Activation and ECM Support#
The follicle sits in a connective-tissue niche, and a degraded extracellular matrix around a shrinking follicle is part of what makes miniaturization self-reinforcing. AHK-Cu is a potent fibroblast activator in its own right.
"At concentrations of 10–100 μM, AHK-Cu increases type I collagen production in normal human dermal fibroblasts by around 300% compared to control." — MedChemExpress, Copper Tripeptide-3 Product Data Sheet, 2023
The collagen-stimulation window sits at much higher concentrations than the DPC mitogenic window, which is why aesthetics-focused users applying AHK-Cu to the hairline and temples tend to notice skin-quality improvements in the same zones as their hair gains — the serum is hitting two dose-windows in the same tissue.
Penetration Profile and Delivery#
Mechanism only matters if the peptide reaches the follicle. AHK-Cu sits right at the edge of the classic permeability rule.
"Peptides with a molecular weight under 500 Da, such as AHK-Cu, can potentially penetrate the stratum corneum, especially when formulated in proper vehicles." — Gorouhi F & Maibach HI, International Journal of Cosmetic Science, 2009
At 415.93 Da, AHK-Cu clears the 500 Da threshold, but the copper complex is charged and hydrophilic, so diffusivity is genuinely limited in a plain aqueous carrier. Two factors salvage real-world delivery: first, hydroethanolic, liposomal, and ionic-liquid microemulsion vehicles materially improve penetration; second, the N-terminal alanine resists enzymatic degradation better than the glycine in GHK-Cu, lengthening the window in which intact peptide can reach the dermal papilla.
"AHK-Cu features an N-terminal alanine that provides greater resistance to enzymatic degradation than GHK-Cu, potentially enhancing scalp delivery." — Bulk Naturals Wholesale, AHK-Cu Ingredient Brief, 2023
The community-standard workaround — microneedling at 0.5–1.5 mm followed immediately by peptide serum — is a mechanism-level shortcut: the stratum corneum is physically bypassed, and the wound-healing cascade triggered by the needles is exactly the signaling context AHK-Cu was evolved to amplify.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 0.5–1 mg | Once daily | Documented entry-level range |
| Mid | 1–5 mg | Once daily | Most commonly studied range |
| High | 5–10 mg | Once daily | Concentrations refer to mg per mL of topical serum (0.05–1% w/v range). Apply roughly 1 mL to the scalp once daily; twice daily at lower concentrations is used in some protocols. Keep application separated in time from vitamin C serums and from minoxidil to avoid vehicle interactions. |
Cycle length & outcomes
Documented cycle
12–52 weeks
Plateau after
26 wks
Cycle Length & Onset Timing#
AHK-Cu is a slow-burn hair compound, not an acute performance tool. Unlike BPC-157 or TB-500 where a 4-week window can produce visible tissue repair, copper-peptide follicle response operates on the hair-cycle clock — anagen re-entry, DPC proliferation, and shaft caliber shifts that take 12–16 weeks minimum to photograph and 6 months to evaluate honestly. Users who bail at week 8 because "nothing happened" have simply quit before the biology finished its first cycle.
There is no loading phase and no taper. The peptide is non-hormonal, so discontinuation does not trigger a rebound endocrine effect — but like minoxidil and finasteride, gains are retained only as long as administration continues. Stop the serum and the follicle loses its trophic signal; within 3–6 months the scalp drifts back toward its genetically programmed trajectory.
Protocol by Goal#
| Goal | Cycle Length | Concentration | Frequency |
|---|---|---|---|
| Tolerability ramp / first-time users | 4–8 weeks | 0.05–0.1% AHK-Cu | 1 mL once daily |
| AGA maintenance (layered on fin/min) | 6+ months, continuous | 0.1–0.2% AHK-Cu + 0.1–0.2% GHK-Cu | 1 mL once daily |
| Active follicle rescue | 6–12 months, continuous | 0.2–0.5% AHK-Cu + 0.2% GHK-Cu | 1 mL once or twice daily |
| Microneedling-potentiated protocol | 6-month evaluation blocks | 0.2–0.5% AHK-Cu + GHK-Cu | Daily serum + 0.5 mm weekly or 1.0–1.5 mm every 10–14 days |
| On-cycle hair insurance (AAS users) | Pre-cycle through post-cycle | 0.1–0.2% AHK-Cu + 0.1% GHK-Cu | 1 mL once daily |
| Dual skin + hairline (aesthetics) | Continuous | 0.1–0.3% AHK-Cu | 1 mL once daily |
Onset Timing#
The follicle response is biphasic in time as well as dose:
- Weeks 0–4: nothing visible. DPC-level proliferation and VEGF upregulation are happening, but the hair shaft hasn't caught up yet. Expect a possible mild initial shed as dormant follicles cycle into anagen — this is a positive signal, not a failure.
- Weeks 4–12: shed reduction becomes noticeable. Shower drain and pillow counts drop first; density is not yet visibly different.
- Weeks 12–16: first photographable results. Caliber thickening of miniaturized hairs in the hairline and crown; vellus-to-terminal conversion begins.
- Weeks 16–26: primary evaluation window. This is where the cycle is judged — month 6 photographs under identical lighting vs. month 0 baseline.
- Weeks 26–52: plateau and maintenance. The
maxEfficacyWeeksof 26 reflects the point at which additional months of the same protocol deliver diminishing marginal density. Continued administration holds the gain; it does not keep compounding indefinitely.
"The tripeptide-copper complex promoted proliferation of human DPCs at 10⁻¹² to 10⁻⁹ M, and elongated human hair follicles ex vivo." — Pyo et al., Archives of Pharmacal Research (2007)
Loading, Tapering, and Holidays#
- No loading phase. The Pyo dose-response is biphasic — concentrations above ~10⁻⁸ M actively inhibit follicle elongation. Front-loading high concentrations is counterproductive.
- No taper on discontinuation. AHK-Cu has no hormonal axis to unwind. The follicle simply stops receiving the trophic signal.
- Cycle holidays are not recommended for AGA maintenance. Unlike performance peptides where receptor desensitization is a concern, copper peptides have no documented tachyphylaxis at topical concentrations. Continuous administration is the norm.
- Formulation refresh every 4–6 weeks. Reconstituted serum degrades in solution. Rotate batches rather than stockpile.
AHK-Cu vs Minoxidil vs Finasteride — Where It Sits in the Cycle#
These three are not interchangeable and should not be cycled against each other.
- vs minoxidil: minoxidil is a vasodilator and anagen-phase extender acting through sulfotransferase-activated metabolites. AHK-Cu is a DPC trophic signal acting through Bcl-2/Bax and VEGF. Different mechanisms — they stack rather than compete. Minoxidil is the more evidence-backed first-line; AHK-Cu is the adjunct.
- vs finasteride: finasteride inhibits systemic 5α-reductase and lowers scalp DHT. AHK-Cu does not meaningfully lower DHT and is not a 5-ARI substitute. For male-pattern hair loss, finasteride (or topical fin/dut, or topical AR antagonists like RU58841) does the androgen half of the job; AHK-Cu does the trophic half.
- Layering logic: the foundation is DHT control (oral or topical 5-ARI, or topical AR antagonist) + minoxidil. AHK-Cu + GHK-Cu is the third layer — a follicle-survival and perifollicular-vascular support that the first two don't directly address.
Bloodwork & Monitoring#
Topical AHK-Cu at 0.1–0.5% does not warrant a standard bloodwork cadence. Practical monitoring:
- Baseline + month 6 scalp photos under identical lighting, angle, and part — the only real outcome metric.
- Shed count diary weeks 0–12 to catch the transient initial shed and confirm it resolves.
- Annual serum copper + ceruloplasmin only for users stacking daily topical copper peptide with oral copper supplementation or running mesotherapy protocols at frequency.
- Patch test a 1 cm² skin area for 72 hours before scaling the first bottle to full scalp coverage.
"Copper peptides stimulate the secretion of growth factors such as VEGF and suppress molecules like TGF-β1, modulating perifollicular vascularization and tissue remodeling." — Pickart & Margolina, International Journal of Molecular Sciences (2018)
Run the protocol with realistic expectations on a 6-month evaluation clock, layer it correctly on top of DHT control and minoxidil, and AHK-Cu earns its slot as the trophic third pillar of a serious hair stack.
Risks & mistakes
Common (most users)#
AHK-Cu has one of the cleanest topical safety profiles in the hair-retention toolkit. At community-standard concentrations (0.1–0.5%) applied once daily, the overwhelming majority of users report nothing beyond minor cosmetic quirks.
- Transient blue/green tint at the application site — purely cosmetic, from the Cu²⁺ ion. Rinses off; no clinical significance.
- Mild scalp tackiness or residue — vehicle-driven (glycerin, ethanol). Reformulation into a lighter hydroethanolic carrier or a liposomal base resolves it.
- Faint stinging on first application — usually the ethanol fraction of the vehicle meeting microabraded scalp, especially on microneedling days. Drop to an aqueous/liposomal carrier, or separate copper peptide application from microneedling by 12+ hours.
- Early shed (weeks 2–6) — not unique to AHK-Cu; any intervention that shifts follicles toward anagen re-entry can trigger a synchronization shed. Photograph the scalp at baseline and hold course for at least 12 weeks before judging response.
Uncommon (dose-dependent or individual)#
- Contact dermatitis / erythema — usually traceable to the vehicle (propylene glycol, preservatives) rather than the peptide itself. Switch carriers before abandoning the compound. If irritation persists across vehicles, a patch test for copper sensitivity is warranted.
- Plateau or regression at ultra-high concentrations. The Pyo dose-response is biphasic — nanomolar concentrations stimulate DPC proliferation, while higher concentrations (≥10⁻⁸ M in vitro) inhibited follicle elongation.
"The tripeptide-copper complex promoted proliferation of human DPCs at 10⁻¹² to 10⁻⁹ M, and elongated human hair follicles ex vivo." — Pyo et al., Archives of Pharmacal Research (2007)
Commercial serums are formulated far above this window to compensate for penetration losses, but running 5–10% DIY concentrations chronically is not additive and may be counterproductive. Stay in the 0.1–0.5% community range.
- Oxidative instability when stacked badly. Co-applying AHK-Cu serum with an ascorbic acid (vitamin C) serum in the same pass reduces Cu²⁺ to Cu¹⁺ and destabilizes the complex — users often misread the loss of efficacy as a "side effect." Separate the two by at least several hours.
- Interaction with minoxidil vehicle. Layering copper peptide serum directly on top of wet minoxidil (especially PG-based foam/solution) can produce local tackiness and reduced delivery of both. Run them on opposite ends of the day.
Rare but serious#
- Copper hypersensitivity reactions — true allergic contact dermatitis to copper is uncommon but documented. Presenting as expanding pruritic erythema, vesiculation, or eczematous patches beyond the application zone. Discontinue and consider a dermatology patch test.
- Folliculitis or secondary infection on microneedled scalp — not a direct effect of AHK-Cu, but users who needle aggressively (1.5 mm) and then apply non-sterile DIY serum risk introducing pathogens. Use sterile vehicles (bacteriostatic water reconstitution), alcohol-swab the dermaroller, and do not apply serum to visibly broken or bleeding skin.
- Systemic copper accumulation — not documented from topical use at community concentrations, but theoretically possible in users stacking heavy daily topical copper peptide + oral copper supplementation + mesotherapy. Annual serum copper and ceruloplasmin is reasonable insurance for this specific stack.
Hard contraindications#
- Wilson's disease or any genetic copper-overload disorder — no intradermal or mesotherapy administration; topical use on intact skin is low-risk but not zero-risk.
- Active scalp dermatitis, seborrheic flare, folliculitis, or open wounds — defer until the scalp barrier has healed. Do not apply copper peptide to compromised skin.
- Known copper or peptide hypersensitivity.
- Intradermal/mesotherapy injection into non-sterile reconstituted material — mesotherapy is only acceptable with properly filtered, sterile-reconstituted peptide. DIY scalp injection of kitchen-table serums is the fastest way to turn a benign compound into a cellulitis case.
Gender, PCT, and stacking considerations#
AHK-Cu is non-hormonal. No androgenic or estrogenic activity, no 5-alpha-reductase inhibition at the systemic level, no HPTA suppression, and no documented effect on libido, erectile function, or semen parameters. PCT does not apply. This is precisely why it earns a place in "finasteride-free" hair stacks for users who discontinued oral 5-ARIs over sexual or mood side effects — the copper peptide layer adds DPC trophic support without re-introducing systemic endocrine risk.
- Female users: safe at standard topical concentrations; the Pyo follicle donor pool was mixed. No virilization potential (there is no androgenic mechanism to virilize through).
- Pregnancy / breastfeeding: no dedicated safety data. The sensible default is to pause during pregnancy and lactation given the absence of studies, not because of a known signal.
- On-cycle AAS users: no documented interaction with testosterone, nandrolone, trenbolone, oral AAS, SARMs, oral or topical finasteride/dutasteride, topical RU58841/pyrilutamide, oral or topical minoxidil, or isotretinoin. AHK-Cu layers cleanly on top of any of these — but it is an adjunct, not a substitute for DHT-lowering or AR-blocking agents in androgen-driven hair loss.
Expectation management is the real "side effect" to plan around: users who run AHK-Cu as monotherapy for progressing androgenetic alopecia and expect it to replace minoxidil or 5-AR inhibition will be disappointed. Used as a trophic layer in a proper stack, against a realistic 3–6 month photographic timeline, it earns its place.
Stack & combine
FAQ — AHK-Cu
Where to buy
Real Peptides
Affiliate link — we may earn a commission at no cost to you.
- AHK-CUBuy AHK-Cu
Research & citations
5 studies cited on this page.
Conclusion
AHK-Cu is a go-to copper peptide for the hair-loss community when the target is follicle rescue, scalp trophism, and stacking on top of fin/min or antiandrogen protocols — not as a standalone. Its mechanism is well-documented at the DPC, with a biphasic dose response where more does not always mean better.
Key takeaways:
- Typical topical concentration: 0.1–0.5% AHK-Cu serum, applied once daily to the scalp
- Serum is usually co-formulated with GHK-Cu for synergistic follicle and collagen support
- Cycle length: 12–26 weeks minimum to assess visible response; continuous use is standard for maintenance
- Stacks best with foundational hair protocols — 5-AR inhibitors (finasteride/dutasteride, oral or topical), minoxidil, or topical AR antagonists (RU58841, pyrilutamide) for AGA
- Microneedling (0.5–1.5 mm rollers/stamps) meaningfully boosts follicular delivery and is a common add-on
- Side effects are rare and local (irritation, tinting); no systemic or sexual side effect profile
As a research compound, AHK-Cu remains one of the best-tolerated and easy-to-layer peptide adjuncts for anyone serious about a comprehensive hair-loss stack.